Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia

C. R. Sirtori, G. Franceschini, G. Gianfranceschi, M. Sirtori, G. Montanari, E. Tremoli, P. Maderna, S. Colli, F. Zoppi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The effects of gemfibrozil on plasma lipoprotein distribution and composition and on platelet function were investigated in 11 patients with stable hypertriglyceridemia, six belonging to Fredrickson type IIb and five to type IV. Gemfibrozil (600 mg twice a day) significantly reduced total and very low density lipoprotein (VLDL)-associated triglyceridemia (respectively -32.4% and -40.4%, after 6 weeks of treatment). No significant variations were noted in the lipid components of low-density lipoproteins; by contrast, a marked increase (18%) was detected in high-density lipoprotein (HDL)-associated cholesterol. Comparison of the two patient groups (type IIb and type IV) showed that those with type IIb had both a more significant reduction of triglyceridemia and a more marked increase of HDL-cholesterol. Apolipoprotein B levels were reduced in both groups (-12%) with no change in apolipoprotein AI. The cholesterol content in the HDL subfractions, separated by rate zonal ultracentrifugation, was raised in HDL3 (18%) and in HDL2 (14%). Both particles also showed significant increases of the cholesterol/protein and the cholesterol/phospholipid ratios. A non-statistically significant decrease in collagen-induced aggregation and in the release of thromboxane B2 was noted after treatment. These findings suggest that, similar to what was recently reported in normal individuals and in laboratory animals, the probable mode of action of gemfibrozil is in reducing the secretion of atherogenic lipoproteins, particularly VLDL, while stimulating the production of small HDL particles.

Original languageEnglish
Pages (from-to)279-286
Number of pages8
JournalThe Journal of Laboratory and Clinical Medicine
Volume110
Issue number3
Publication statusPublished - 1987

Fingerprint

Gemfibrozil
Apolipoproteins
Hypertriglyceridemia
Lipoproteins
Blood Platelets
VLDL Lipoproteins
Cholesterol
HDL Lipoproteins
HDL Cholesterol
Thromboxane B2
Ultracentrifugation
Apolipoprotein A-I
Laboratory Animals
Apolipoproteins B
LDL Lipoproteins
Phospholipids
Collagen
Lipids
Therapeutics
Proteins

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia. / Sirtori, C. R.; Franceschini, G.; Gianfranceschi, G.; Sirtori, M.; Montanari, G.; Tremoli, E.; Maderna, P.; Colli, S.; Zoppi, F.

In: The Journal of Laboratory and Clinical Medicine, Vol. 110, No. 3, 1987, p. 279-286.

Research output: Contribution to journalArticle

Sirtori, CR, Franceschini, G, Gianfranceschi, G, Sirtori, M, Montanari, G, Tremoli, E, Maderna, P, Colli, S & Zoppi, F 1987, 'Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia', The Journal of Laboratory and Clinical Medicine, vol. 110, no. 3, pp. 279-286.
Sirtori, C. R. ; Franceschini, G. ; Gianfranceschi, G. ; Sirtori, M. ; Montanari, G. ; Tremoli, E. ; Maderna, P. ; Colli, S. ; Zoppi, F. / Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia. In: The Journal of Laboratory and Clinical Medicine. 1987 ; Vol. 110, No. 3. pp. 279-286.
@article{33b330a6ca404d6281b7ed9af0fe6e08,
title = "Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia",
abstract = "The effects of gemfibrozil on plasma lipoprotein distribution and composition and on platelet function were investigated in 11 patients with stable hypertriglyceridemia, six belonging to Fredrickson type IIb and five to type IV. Gemfibrozil (600 mg twice a day) significantly reduced total and very low density lipoprotein (VLDL)-associated triglyceridemia (respectively -32.4{\%} and -40.4{\%}, after 6 weeks of treatment). No significant variations were noted in the lipid components of low-density lipoproteins; by contrast, a marked increase (18{\%}) was detected in high-density lipoprotein (HDL)-associated cholesterol. Comparison of the two patient groups (type IIb and type IV) showed that those with type IIb had both a more significant reduction of triglyceridemia and a more marked increase of HDL-cholesterol. Apolipoprotein B levels were reduced in both groups (-12{\%}) with no change in apolipoprotein AI. The cholesterol content in the HDL subfractions, separated by rate zonal ultracentrifugation, was raised in HDL3 (18{\%}) and in HDL2 (14{\%}). Both particles also showed significant increases of the cholesterol/protein and the cholesterol/phospholipid ratios. A non-statistically significant decrease in collagen-induced aggregation and in the release of thromboxane B2 was noted after treatment. These findings suggest that, similar to what was recently reported in normal individuals and in laboratory animals, the probable mode of action of gemfibrozil is in reducing the secretion of atherogenic lipoproteins, particularly VLDL, while stimulating the production of small HDL particles.",
author = "Sirtori, {C. R.} and G. Franceschini and G. Gianfranceschi and M. Sirtori and G. Montanari and E. Tremoli and P. Maderna and S. Colli and F. Zoppi",
year = "1987",
language = "English",
volume = "110",
pages = "279--286",
journal = "Journal of Laboratory and Clinical Medicine",
issn = "0022-2143",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia

AU - Sirtori, C. R.

AU - Franceschini, G.

AU - Gianfranceschi, G.

AU - Sirtori, M.

AU - Montanari, G.

AU - Tremoli, E.

AU - Maderna, P.

AU - Colli, S.

AU - Zoppi, F.

PY - 1987

Y1 - 1987

N2 - The effects of gemfibrozil on plasma lipoprotein distribution and composition and on platelet function were investigated in 11 patients with stable hypertriglyceridemia, six belonging to Fredrickson type IIb and five to type IV. Gemfibrozil (600 mg twice a day) significantly reduced total and very low density lipoprotein (VLDL)-associated triglyceridemia (respectively -32.4% and -40.4%, after 6 weeks of treatment). No significant variations were noted in the lipid components of low-density lipoproteins; by contrast, a marked increase (18%) was detected in high-density lipoprotein (HDL)-associated cholesterol. Comparison of the two patient groups (type IIb and type IV) showed that those with type IIb had both a more significant reduction of triglyceridemia and a more marked increase of HDL-cholesterol. Apolipoprotein B levels were reduced in both groups (-12%) with no change in apolipoprotein AI. The cholesterol content in the HDL subfractions, separated by rate zonal ultracentrifugation, was raised in HDL3 (18%) and in HDL2 (14%). Both particles also showed significant increases of the cholesterol/protein and the cholesterol/phospholipid ratios. A non-statistically significant decrease in collagen-induced aggregation and in the release of thromboxane B2 was noted after treatment. These findings suggest that, similar to what was recently reported in normal individuals and in laboratory animals, the probable mode of action of gemfibrozil is in reducing the secretion of atherogenic lipoproteins, particularly VLDL, while stimulating the production of small HDL particles.

AB - The effects of gemfibrozil on plasma lipoprotein distribution and composition and on platelet function were investigated in 11 patients with stable hypertriglyceridemia, six belonging to Fredrickson type IIb and five to type IV. Gemfibrozil (600 mg twice a day) significantly reduced total and very low density lipoprotein (VLDL)-associated triglyceridemia (respectively -32.4% and -40.4%, after 6 weeks of treatment). No significant variations were noted in the lipid components of low-density lipoproteins; by contrast, a marked increase (18%) was detected in high-density lipoprotein (HDL)-associated cholesterol. Comparison of the two patient groups (type IIb and type IV) showed that those with type IIb had both a more significant reduction of triglyceridemia and a more marked increase of HDL-cholesterol. Apolipoprotein B levels were reduced in both groups (-12%) with no change in apolipoprotein AI. The cholesterol content in the HDL subfractions, separated by rate zonal ultracentrifugation, was raised in HDL3 (18%) and in HDL2 (14%). Both particles also showed significant increases of the cholesterol/protein and the cholesterol/phospholipid ratios. A non-statistically significant decrease in collagen-induced aggregation and in the release of thromboxane B2 was noted after treatment. These findings suggest that, similar to what was recently reported in normal individuals and in laboratory animals, the probable mode of action of gemfibrozil is in reducing the secretion of atherogenic lipoproteins, particularly VLDL, while stimulating the production of small HDL particles.

UR - http://www.scopus.com/inward/record.url?scp=0023630285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023630285&partnerID=8YFLogxK

M3 - Article

VL - 110

SP - 279

EP - 286

JO - Journal of Laboratory and Clinical Medicine

JF - Journal of Laboratory and Clinical Medicine

SN - 0022-2143

IS - 3

ER -